TherapeuticsMD (TXMD) Operating Leases (2019 - 2026)

TherapeuticsMD (TXMD) has reported Operating Leases for 8 consecutive years, with $4.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Leases fell 20.93% year-over-year to $4.5 million; the trailing twelve-month figure through Jun 2026 stood at $4.5 million (down 20.93% YoY), and the FY2025 full-year result was $5.1 million, down 28.61% from the prior year.
• Operating Leases retreated to $4.5 million in Q2 2026 per TXMD's latest filing, from $4.8 million in the prior quarter.
• Across five years, Operating Leases topped out at $8.0 million in Q4 2023 and bottomed at $4.5 million in Q2 2026.
• Historically, Operating Leases has averaged $6.5 million across 5 years, with a median of $6.8 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Operating Leases increased 8.63% in 2023, then declined 28.61% in 2025.
• Over 5 years, Operating Leases stood at $7.4 million in 2022, then climbed by 8.63% to $8.0 million in 2023, then declined by 10.37% to $7.2 million in 2024, then slipped by 28.61% to $5.1 million in 2025, then slipped by 11.73% to $4.5 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $4.5 million, $4.8 million, and $5.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.